10 results
8-K
EX-99.1
RLYB
Rallybio Corporation
9 Nov 23
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
8:10am
expect to finalize the toxicology package for RLYB212, our anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune … for RLYB212, an anti-HPA-1a monoclonal antibody being developed for the prevention of FNAIT:
Finalize toxicology package for RLYB212, including maternal
10-K
q8jv28lqo2377i4q7qvf
15 Mar 22
Annual report
4:31pm
S-1
EX-10.2
y97tk jy95ra
2 Jul 21
IPO registration
4:28pm
S-1
EX-10.3
mdub8
2 Jul 21
IPO registration
4:28pm
DRS
EX-10.2
eod84h6v
27 Apr 21
Draft registration statement
12:00am
DRS
EX-10.3
ird33mcwx01fyfen
27 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next